Optimizing -lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective?

被引:91
作者
Delattre, Isabelle K. [1 ,2 ]
Taccone, Fabio S. [3 ]
Jacobs, Frederique [4 ]
Hites, Maya [4 ]
Dugernier, Thierry [5 ]
Spapen, Herbert [6 ]
Laterre, Pierre-Francois [7 ]
Wallemacq, Pierre E. [2 ]
Van Bambeke, Francoise [1 ]
Tulkens, Paul M. [1 ]
机构
[1] Catholic Univ Louvain, Louvain Drug Res Inst, Brussels, Belgium
[2] Clin Univ St Luc, Dept Clin Chem, Brussels, Belgium
[3] Hop Erasme, Dept Intens Care, Brussels, Belgium
[4] Hop Erasme, Dept Infect Dis, Brussels, Belgium
[5] Clin St Pierre, Dept Intens Care, Ottignies, Belgium
[6] Univ Ziekenhuis Brussel, Dept Intens Care, Brussels, Belgium
[7] Clin Univ St Luc, Dept Intens Care, Brussels, Belgium
关键词
B-lactams; critically-ill patients; PK; PD targets; first dose; maximal efficacy; CARE-UNIT PATIENTS; MINIMUM INHIBITORY CONCENTRATION; FEBRILE NEUTROPENIC PATIENTS; RENAL REPLACEMENT THERAPY; CONTINUOUS VENOVENOUS HEMODIAFILTRATION; STEADY-STATE PHARMACOKINETICS; DEFINING ANTIBIOTIC LEVELS; MORBIDLY OBESE-PATIENTS; LOWER RESPIRATORY-TRACT; POPULATION PHARMACOKINETICS;
D O I
10.1080/14787210.2017.1338139
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Introduction: The pharmacokinetic/pharmacodynamic index determining -lactam activity is the percentage of the dosing interval (%T) during which their free serum concentration remains above a critical threshold over the minimum inhibitory concentration (MIC). Regrettably, neither the value of %T nor that of the threshold are clearly defined for critically-ill patients.Areas covered: We review and assess the targets proposed for -lactams in critical illness by screening the literature since 1997. Depending on the study intention (clinical cure vs. suppression of resistance), targets proposed range from 20%T>1xMIC to 100%T>5xMIC. Assessment and comparative analysis of their respective clinical efficacy suggest that a value of 100%T>4xMIC may be needed. Simulation studies, however, show that this target will not be reached at first dose for the majority of critically-ill patients if using the most commonly recommended doses.Expert commentary: Considering that critically-ill patients are highly vulnerable and likely to experience antibiotic underexposure, and because effective initial treatment is a key determinant of clinical outcome, we support the use of a target of 100%T>4xMIC, which could not only maximize efficacy but also minimize emergence of resistance. Clinical and microbiological studies are needed to test for the feasibility and effectiveness of reaching such a demanding target.
引用
收藏
页码:677 / 688
页数:12
相关论文
共 104 条
[1]   Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort [J].
Abdul-Aziz, Mohd H. ;
Lipman, Jeffrey ;
Akova, Murat ;
Bassetti, Matteo ;
De Waele, Jan J. ;
Dimopoulos, George ;
Dulhunty, Joel ;
Kaukonen, Kirsi-Maija ;
Koulenti, Despoina ;
Martin, Claude ;
Montravers, Philippe ;
Rello, Jordi ;
Rhodes, Andrew ;
Starr, Therese ;
Wallis, Steven C. ;
Roberts, Jason A. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2016, 71 (01) :196-207
[2]  
Abdul-Aziz MH, 2012, MINERVA ANESTESIOL, V78, P94
[3]   Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia [J].
Aitken, Samuel L. ;
Altshuler, Jerry ;
Guervil, David J. ;
Hirsch, Elizabeth B. ;
Ostrosky-Zeichner, Luis L. ;
Ericsson, Charles D. ;
Tam, Vincent H. .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2015, 45 (05) :541-544
[4]   Modified Augmented Renal Clearance score predicts rapid piperacillin and tazobactam clearance in critically ill surgery and trauma patients [J].
Akers, Kevin S. ;
Niece, Krista L. ;
Chung, Kevin K. ;
Cannon, Jeremy W. ;
Cota, Jason M. ;
Murray, Clinton K. .
JOURNAL OF TRAUMA AND ACUTE CARE SURGERY, 2014, 77 :S163-S170
[5]   Animal model pharmacokinetics and pharmacodynamics: a critical review [J].
Andes, D ;
Craig, WA .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2002, 19 (04) :261-268
[6]  
Angus B. J., 2000, British Journal of Clinical Pharmacology, V50, P184
[7]   Pharmacokinetics and pharmacodynamics of meropenern in febrile neutropenic patients with bacteremia [J].
Ariano, RE ;
Nyhlén, A ;
Donnelly, JP ;
Sitar, DS ;
Harding, GKM ;
Zelenitsky, SA .
ANNALS OF PHARMACOTHERAPY, 2005, 39 (01) :32-38
[8]   Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis [J].
Asin-Prieto, Eduardo ;
Rodriguez-Gascon, Alicia ;
Troconiz, Inaki F. ;
Soraluce, Amaia ;
Maynar, Javier ;
Angel Sanchez-Izquierdo, Jose ;
Isla, Arantxazu .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (01) :180-189
[9]   Pharmacokinetics of an Extended 4-hour Infusion of Piperacillin-Tazobactam in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy [J].
Awissi, Don-Kelena ;
Beauchamp, Annie ;
Hebert, Elisabeth ;
Lavigne, Viviane ;
Munoz, Danya Lucia ;
Lebrun, Genevieve ;
Savoie, Michel ;
Fagnan, Mylene ;
Amyot, Julie ;
Tetreault, Nicolas ;
Robitaille, Robert ;
Varin, France ;
Lavallee, Christian ;
Pichette, Vincent ;
Leblanc, Martine .
PHARMACOTHERAPY, 2015, 35 (06) :600-607
[10]   Treatment of Gram-negative pneumonia in the critical care setting: is the beta-lactam antibiotic backbone broken beyond repair? [J].
Bassetti, Matteo ;
Welte, Tobias ;
Wunderink, Richard G. .
CRITICAL CARE, 2016, 20